In the fourth quarter, the company is guiding for revenues of approximately $13.5 billion, which is $400 million below the lower end of the previous forecast. This represents a 45 percent growth compared to the fourth quarter of the previous year. Mounjaro accounts for $3.5 billion of the sales, while Zepbound contributes $1.9 billion.
Analysts had expected Mounjaro and Zepbound to bring in $5.34 billion and $2.08 billion, respectively, according to LSEG.
“The sales of Mounjaro and Zepbound showed robust growth in the fourth quarter, and we expect this trend to continue throughout 2025,” says CEO David Ricks.
For 2025, Eli Lilly is guiding for sales to be between $58 and $61 billion, representing a 32 percent increase in the middle of the range compared to the expected revenues for 2024. The consensus estimate is $58.72 billion according to Bloomberg.
The company anticipates contributions from new drugs such as Jaypirca, Ebglyss, Omvoh, and Kisunla, approvals for new indications for existing drugs, the launch of Mounjaro in additional markets, and potentially new treatments for metastatic breast cancer.
“2024 was a pivotal and highly successful year for Lilly, and we expect to continue our momentum in 2025 with strong financial and operational results,” Ricks states.
As Eli Lilly continues to innovate and expand its product portfolio, the pharmaceutical giant is poised for further growth and success in the coming years. The company’s commitment to developing cutting-edge treatments and expanding its global reach is reflected in its optimistic projections for 2025. With a focus on research and development, Eli Lilly is well-positioned to meet the evolving needs of patients and healthcare providers worldwide.